Clinical trials: Resolution
Paroxysmal Atrial Fibrillation (PAF)
INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
The study consisted of 3 parts (Part A, Part B and Part C). Part A was an open-label, randomized, multi center design to evaluate the feasibility of administration of inhaled flecainide in two dosing regimens.
- Trial name
- INSTANT (NCT03539302)
- Testing
- Flecainide Acetate
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 176 people
- Sponsor
- InCarda Therapeutics, Inc.
Venous Thromboembolism
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
To investigate the safety and tolerability of dabigatran etexilate solution in children and to obtain preliminary pharmacokinetic/pharmacodynamic data
- Trial name
- NCT01083732
- Testing
- dabigatran etexilate
- Where
- 7 sites in Canada, Italy and 4 more
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis
Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to…
- Trial name
- NCT01180634
- Testing
- Aeroquin
- Where
- 112 sites in United States, Australia and 3 more
- Volunteers
- 330 people
- Sponsor
- Amgen
Bioavailability, Healthy Subjects
A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution
This clinical study is an open-label, randomized, 4-period, 4-treatment, crossover, single-center, single-dose bioavailability study with alternate methods of administration of crushed naloxegol tablets, 25 mg and of a naloxegol…
- Trial name
- NCT02446171
- Testing
- Naloxegol 25 mg tablet, crushed, suspended in water, given orally, Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube, Naloxegol 25 mg (10 mL oral solution)
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Onychomycosis of Toenails
Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
- Trial name
- NCT01270971
- Testing
- AN2690 Topical Solution, 5%, Solution Vehicle
- Where
- 27 sites in United States
- Volunteers
- 594 people
- Sponsor
- Pfizer
Refractive Error
Lens Wearing Experience and Biocompatibility of a Marketed Multi-Purpose Disinfecting Solution in Silicone Hydrogel and Soft Contact Lens Wearers
The purpose of this study was to describe mean differences in corneal staining (type and area) for OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS) at Day 30 compared to Baseline (Day 0).
- Trial name
- NCT01484938
- Testing
- OPTI-FREE PureMoist
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Alcon Research
Pneumonia, Bacterial
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and…
- Trial name
- INHALE 1 (NCT01799993)
- Testing
- Amikacin Inhalation Solution (BAY41-6551)
- Where
- 65 sites in United States, Australia and 10 more
- Volunteers
- 725 people
- Sponsor
- Bayer
Prader-Willi Syndrome
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
The objective of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in participants with Prader-Willi Syndrome.
- Trial name
- NCT03458416
- Testing
- Cannabidiol Oral Solution
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT02322216
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 383 people
- Sponsor
- Alcon Research
Alzheimer´s Disease
Phase 3 IGIV, 10% in Alzheimer´s Disease
The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.
- Trial name
- NCT01524887
- Testing
- Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%
- Where
- 69 sites in United States, Australia and 6 more
- Volunteers
- 508 people
- Sponsor
- Baxalta now part of Shire
Pulmonary Disease, Chronic Obstructive
Tiotropium / Respimat One-Year Study
To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
- Trial name
- NCT00168831
- Testing
- Tiotropium Inhalation Solution
- Where
- 76 sites in United States, Australia and 13 more
- Volunteers
- 1,007 people
- Sponsor
- Boehringer Ingelheim
Ketosis
A Trial of Intravenous Fluids During Labor
The purpose of this study is to determine if intrapartum use of a glucose-containing solution will improve the outcomes in pregnant women and their babies.
- Trial name
- RARHY (NCT01110005)
- Testing
- D5 Lactated Ringer's Solution (D5LR), Lactated Ringer's Solution (LR)
- Where
- 4 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Safety, Tolerability
Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+
Clinical phase I, controlled, non comparative, open, single center study evaluating the safety and tolerability of ophthalmic solution PRO-172 when applied on the ocular surface of healthy volunteers.
- Conditions
- Safety, Tolerability, Ocular Surface, Ocular Comfort
- Trial name
- PRO-172 (NCT04693429)
- Testing
- Bepotastine Besilate
- Where
- Mexico
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye
Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.
Phase II, comparative, controlled, multicenter, parallel group, open, randomized clinical study. The main outcome variable will be the Ocular Surface Disease Index (OSDI) questionnaire.
- Trial name
- PRO-037 (NCT04704531)
- Testing
- Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID), Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID), Sodium Hyaluronate Ophthalmic 0.4% Six times per day
- Where
- Mexico
- Volunteers
- 141 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Colorectal Cancer, Colorectal Carcinoma
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.
This study evaluates the efficacy, safety and tolerability of NER1006 versus a sodium picosulfate and magnesium salt solution (SP + MS) in adult patients requiring bowel cleansing prior to any procedure that requires a clean…
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colon Cleansing
- Trial name
- NCT02273141
- Testing
- NER1006, Day Before-Only Dosing, SP+MS, Day Before-Only Dosing
- Where
- 19 sites in Germany, Italy and 4 more
- Volunteers
- 515 people
- Sponsor
- Norgine
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
- Trial name
- NCT02674854
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Aerie Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00690794
- Testing
- Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®), Latanoprost ophthalmic solution 0.005% (XALATAN®)
- Volunteers
- 726 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in…
- Trial name
- NCT02108288
- Testing
- OPC-1085EL ophthalmic solution, Carteolol long-acting ophthalmic solution, Latanoprost ophthalmic solution
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Colonoscopy
Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation
The primary objective is to compare the effectiveness and tolerance of the medication named lubiprostone plus a large volume liquid laxative versus placebo which is a look alike medication that has no effect such as a sugar pill…
- Trial name
- PEG (NCT00645801)
- Testing
- lubiprostone (Amitiza)
- Where
- 3 sites in United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Dry Eye
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
The objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- VELOS-3 (NCT05109702)
- Testing
- 0.25% Tanfanercept Ophthalmic Solution
- Where
- 10 sites in United States
- Volunteers
- 260 people
- Sponsor
- HanAll BioPharma Co., Ltd.